Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment

Journal of Controlled Release

Volumn 119, Issue 1, 2007, Pages 41-51

  Westedt, Ulrich ^a   Kalinowski, Marc ^b   Wittmar, Matthias ^a   Merdan, Thomas ^a   Unger, Florian ^a   Fuchs, Jutta ^a   Schäller, Susann ^b   Bakowsky, Udo ^a   Kissel, Thomas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Nanoparticles; Paclitaxel; Poly(vinyl alcohol) graft poly(lactide co glycolide); Restenosis

Indexed keywords

BIODEGRADABLE NANOPARTICLES (NP); PACLITAXEL; PHOTON CORRELATION SPECTROSCOPY (PCS); RESTENOSIS;

BIODEGRADATION; EVAPORATION; MUSCLE; NANOPARTICLES; POLYVINYL ALCOHOLS; SCANNING ELECTRON MICROSCOPY; SOLVENTS;

DRUG DELIVERY;

FLUORESCENT DYE; NANOPARTICLE; OREGON GREEN; PACLITAXEL; POLYGLACTIN; POLYVINYL ALCOHOL; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BALLOON CATHETER; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENCAPSULATION; EVAPORATION; FLUORESCENCE; ILIAC ARTERY; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; QUANTUM YIELD; RABBIT; RESTENOSIS; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; CONSTRICTION, PATHOLOGIC; DRUG DELIVERY SYSTEMS; GRAFT OCCLUSION, VASCULAR; ILIAC ARTERY; LACTIC ACID; MALE; NANOPARTICLES; PACLITAXEL; POLYGLYCOLIC ACID; POLYMERS; RABBITS;

EID: 34147125914     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.01.009     Document Type: Article

References (54)

1. Chorny M., Fishbein I., and Golomb G. Drug delivery systems for treatment of restenosis. Crit. Rev. Ther. Drug Carr. Syst. 17 3 (2000) 249-284
2. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J. Vasc. Surg. 31 1 Pt 2 (2000) S1-S296
3. Jaemsen T., Manninen H., Tulla H., and Matsi P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J. Vasc. Interv. Radiol. 13 5 (2002) 455-463
4. Popma J.J., Califf R.M., and Topol E.J. Clinical trials of restenosis after coronary angioplasty. Circulation 84 3 (1991) 1426-1436
5. Bauters C., and Isner J.M. The biology of restenosis. Prog. Cardiovasc. Dis. 40 2 (1997) 107-116
6. Bhargava B., Karthikeyan G., Abizaid A.S., and Mehran R. New approaches to preventing restenosis. Br. Med. J. 327 7409 (2003) 274-279
7. Muller D.W., Topol E.J., Abrams G.D., Gallagher K.P., and Ellis S.G. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J. Am. Coll. Cardiol. 20 2 (1992) 460-466
8. Mitchel J.F., Fram D.B., Palme D.F., Foster R., Hirst J.A., Azrin M.A., Bow L.M., Eldin A.M., Waters D.D., and McKay R.G. Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies. Circulation 91 3 (1995) 785-793
9. Rome J., Shayani V., Flugelman M., Newman K., Farb A., Virmani R., and Dichek D. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler. Thromb. 14 1 (1994) 148-161
10. Gradus-Pizlo I., Wilensky R.L., March K.L., Fineberg N., Michaels M., Sandusky G.E., and Hathaway D.R. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J. Am. Coll. Cardiol. 26 6 (1995) 1549-1557
11. Nasser T.K., Wilensky R.L., Mehdi K., and March K.L. Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: quantitation and localization by confocal scanning laser microscopy. Am. Heart J. 131 5 (1996) 892-898
12. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., Wild D.H., Brehm B.R., Riessen R., Koveker G., and Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 2 (1997) 636-645
13. Herdeg C., Oberhoff M., Baumbach A., Blattner A., Axel D.I., Schroder S., Heinle H., and Karsch K.R. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. Cardiol. 35 7 (2000) 1969-1976
14. Rowinsky E.K., and Donehower R.C. Paclitaxel (Taxol). N. Engl. J. Med. 332 15 (1995) 1004-1014
15. H. Fessi, J.P. Devissaguet, F. Puisieux, C. Thies, Process of the preparation of dispersable colloidal systems of a substance in the form of nanoparticles formation of colloidal nanoparticles, 5, 118,528, 1992.
16. Fishbein I., Chorny M., Rabinovich L., Banai S., Gati I., and Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J. Control. Release 65 1-2 (2000) 221-229
17. Song C., Labhasetwar V., Cui X., Underwood T., and Levy R.J. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J. Control. Release 54 2 (1998) 201-211
18. Mu L., and Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 86 1 (2003) 33-48
19. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70 1-2 (2001) 1-20
20. Breitenbach A., and Kissel T. Biodegradable comb polyesters: Part 1- synthesis, characterisation and structural analysis of PLA and PLGA grafted onto water-soluble PVA as backbone. Polymers 39 14 (1998) 3261-3271
21. Pistel K.F., Breitenbach A., Zange R., and Kissel T. Brush-like biodegradable polyesters, Part III, protein release from microspheres of poly(vinyl alcohol)-graft-poly(d,l-lactic-co-glycolic acid). J. Control. Release 73 1 (2001) 7-20
22. Breitenbach A., Pistel K.F., and Kissel T. Biodegradable comb polyesters Part II. Erosion and release properties of PVA-g-PLG. Polymers 41 (2000) 4781-4792
23. Jung T., Breitenbach A., and Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J. Control. Release 67 2-3 (2000) 157-169
24. S.M. Ropiak, Multiple Hole Drug Delivery Balloon, US 5,860,954, 1999.
25. Oberle V., Bakowsky U., Zuhorn I.S., and Hoekstra D. Lipoplex formation under equilibrium conditions reveals a three-step mechanism. Biophys. J. 79 3 (2000) 1447-1454
26. Axel D.I., Brehm B.R., Wolburg-Buchholz K., Betz E.L., Koveker G., and Karsch K.R. Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells. J. Vasc. Res. 33 4 (1996) 327-339
27. Quintanar-Guerrero D., Allémann E., Doelker E., and Fessi H. A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique. Colloid Polym. Sci. 275 7 (1997) 640-647
28. Feng S., and Huang G. Effects of emulsifiers on the controlled release of Paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Release 71 1 (2001) 53-69
29. Fonseca C., Simoes S., and Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 83 2 (2002) 273-286
30. Jingwei X., and Chi-Hwa W. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm. Res. 22 12 (2005) 2079-2090
31. Westedt U., Wittmar M., Hellwig M., Hanefeld P., Greiner A., Schaper A.K., and Kissel T. Paclitaxel releasing films consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) and their potential as biodegradable stent coatings. J. Control. Release 111 1-2 (2006) 235-246
32. Chawla J.S., and Amiji M.M. Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles. AAPS PharmSci 5 1 (2003) E3
33. Panyam J., and Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 20 2 (2003) 212-220
34. Chorny M., Fishbein I., Danenberg H.D., and Golomb G. Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. J. Control. Release 83 3 (2002) 401-414
35. Feng S.S., Mu L., Win K.Y., and Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11 4 (2004) 413-424
36. Muller R.H., Maeder K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm Biopharm. 50 1 (2000) 161-177
37. Chawla J.S., and Amiji M.M. Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm. 249 1-2 (2002) 127-138
38. Brigger I., Chaminade P., Marsaud V., Appel M., Besnard M., Gurny R., Renoir M., and Couvreur P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 214 1-2 (2001) 37-42
39. Suh H., Jeong B., Rathi R., and Kim S.W. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J. Biomed. Mater. Res. 42 2 (1998) 331-338
40. Foster K.A., Yazdanian M., and Audus K.L. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J. Pharm. Pharmacol. 53 1 (2001) 57-66
41. Panyam J., Sahoo S.K., Prabha S., Bargar T., and Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d,l-lactide-co-glycolide) nanoparticles. Int. J. Pharm. 262 1-2 (2003) 1-11
42. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., and Labhasetwar V. Rapid endo-lysosomal escape of poly(d,l-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16 10 (2002) 1217-1226
43. Kim D.W., Kwon J.S., Kim Y.G., Kim M.S., Lee G.S., Youn T.J., and Cho M.C. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 109 12 (2004) 1558-1563
44. Yasuda S., Noguchi T., Gohda M., Arai T., Tsutsui N., Nakayama Y., Matsuda T., and Nonogi H. Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model. Cardiovasc. Res. 53 2 (2002) 481-486
45. Fishbein I., Chorny M., Banai S., Levitzki A., Danenberg H.D., Gao J., Chen X., Moerman E., Gati I., Goldwasser V., and Golomb G. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler. Thromb. Vasc. Biol. 21 9 (2001) 1434-1439
46. Westedt U., Barbu-Tudoran L., Schaper A.K., Kalinowski M., Alfke H., and Kissel T. Deposition of nanoparticles in the arterial vessel by porous balloon catheters: localisation by confocal laser scanning microscopy and transmission electron microscopy. AAPS PharmSci 4 4 (2002) (article 41)
47. Kimura T., Miyauchi K., Yamagami S., Daida H., and Yamaguchi H. Local delivery infusion pressure is a key determinant of vascular damage and intimal thickening. Jpn. Circ. J. 62 4 (1998) 299-304
48. Westedt U., Barbu-Tudoran L., Schaper A.K., Kalinowski M., Alfke H., and Kissel T. Effects of different application parameters on penetration characteristics and arterial vessel wall integrity after local nanoparticle delivery using a porous balloon catheter. Eur. J. Pharm. Biopharm. 58 1 (2004) 161-168
49. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., and Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50 4 (1966) 219-244
50. Teirstein P.S., and Kuntz R.E. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. Circulation 104 21 (2001) 2620-2626
51. Sousa J.E., Costa M.A., Abizaid A., Sousa A.G., Feres F., Mattos L.A., Centemero M., Maldonado G., Abizaid A.S., Pinto I., Falotico R., Jaeger J., Popma J.J., and Serruys P.W. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 107 1 (2003) 24-27
52. Cruz C.P., Eidt J., Drouilhet J., Brown A.T., Wang Y., Barnes C.S., and Moursi M.M. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J. Vasc. Surg. 34 4 (2001) 724-729
53. Oster C.G., Wittmar M., Unger F., Barbu-Tudoran L., Schaper A.K., and Kissel T. Design of amine-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. Pharm. Res. 21 6 (2004) 927-931
54. Dailey L.A., Wittmar M., and Kissel T. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J. Control. Release 101 1-3 (2005) 137-149